Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange ...
24 July 2020 - 4:00PM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a
biopharmaceutical company focusing on the development of novel
therapeutics to address global unmet medical needs, today is
pleased to announce that its Class A Ordinary Shares has commenced
trading on the Professional Compartment of Euronext in Paris under
the Euronext ticker symbol “APM” and ISIN Code: KYG6096M1069.
Aptorum Group’s Class A Ordinary Shares continues to be listed on
the Nasdaq Global Market under the symbol APM.
The 7,950,986 Class A Ordinary Shares of Aptorum Group got
admitted to trading on Euronext market in Paris after Aptorum Group
received a visa for its prospectus granted by the French Autorité
des Marchés Financiers on 16 July 2020.
Reed Smith LLP acts as Aptorum Group’s legal advisor and listing
agent. BNP Paribas Securities Services acts as Aptorum Group’s
trading agent.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle current unmet medical needs. Aptorum Group’s current drug
pipeline includes indications in orphan diseases, infectious
diseases and metabolic diseases, a number of which are targeted to
enter clinical trial phases. Aptorum Group is also launching a
women’s health supplement, dioscorea opposita bioactive
nutraceutical tablets marketed under the brand name
NativusWell®.
For more information about Aptorum Group, please visit our
website: www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute "forward-looking statements" within the meaning of the
US Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as "may," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue," or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future and the prospectus that received the
French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020. As a result, the projections included in such forward-looking
statements are subject to change and could be materially different
from those described herein. Aptorum Group assumes no obligation to
update any forward-looking statements contained in this press
release as a result of new information, future events or
otherwise.
This press release is provided ”as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200723005340/en/
Investor relations
Aptorum Group limited Investor Relations Department: Tel:
+852 3953 7700 Email: investor.relations@aptorumgroup.com
Actifin – Financial Communications Europe
Investor relations Ghislaine Gasparetto ggasparetto@actifin.fr
+33 1 56 88 11 22
Redchip – Financial Communications United States
Investor relations RedChip Companies, Inc. dave@redchip.com +1
407 491 4498
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2024 to May 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From May 2023 to May 2024